The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results

David Allie, Patrick Hall, Nicolas W. Shammas, Robert Safian, John R. Laird, John J. Young, Ajay Virmani

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background - High-risk patient characteristics and complexity of percutaneous peripheral intervention (PPI) procedures suggest a need for predictable and reliable anticoagulation. We undertook this study to assess the safety and efficacy of bivalirudin as the procedural anticoagulant in patients undergoing PPI of the renal, iliac, or femoral artery. Methods - This was a prospective, open-label, single arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant (0.75 mg/kg bolus/1.75 mg/kg/hr infusion). The primary endpoint was procedural success defined as residual stenosis ≤ 20%. Secondary endpoints included ischemic events (death, myocardial infarction, unplanned revascularization, and amputation), and bleeding complications, as well as ACT values and times to sheath removal, ambulation, and discharge. Results - 505 patients were enrolled at 26 sites. Procedural success was achieved in 95.0% of patients. Ischemic events were low (1.4%) and similar between vessel types. Protocol-defined major hemorrhage and TIMI major hemorrhage rates were 2.2% and 0.4%, respectively. Mean ACTs were similar among treatment groups (renal 353.8 seconds(s); iliac 335.9s, femoral, 343.5s). Conclusion - Bivalirudin provided consistent anticoagulation and similar outcomes in all vessel types treated at the dose tested. Ischemic and bleeding event rates were low, demonstrating the safe use of bivalirudin as a procedural anticoagulant in PPI.

Original languageEnglish (US)
Pages (from-to)651-656
Number of pages6
JournalJournal of Invasive Cardiology
Volume16
Issue number11
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Blood Vessels
Registries
Anticoagulants
Hemorrhage
Thigh
Kidney
Iliac Artery
Renal Artery
Femoral Artery
Amputation
Walking
Pathologic Constriction
Myocardial Infarction
bivalirudin
Safety
Therapeutics

Keywords

  • Anticoagulation
  • Femoral artery
  • Iliac artery
  • Percutaneous peripheral intervention
  • Renal intervention
  • Unfractionated heparin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Allie, D., Hall, P., Shammas, N. W., Safian, R., Laird, J. R., Young, J. J., & Virmani, A. (2004). The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results. Journal of Invasive Cardiology, 16(11), 651-656.

The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE) : In-hospital and 30-day results. / Allie, David; Hall, Patrick; Shammas, Nicolas W.; Safian, Robert; Laird, John R.; Young, John J.; Virmani, Ajay.

In: Journal of Invasive Cardiology, Vol. 16, No. 11, 11.2004, p. 651-656.

Research output: Contribution to journalArticle

Allie, D, Hall, P, Shammas, NW, Safian, R, Laird, JR, Young, JJ & Virmani, A 2004, 'The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results', Journal of Invasive Cardiology, vol. 16, no. 11, pp. 651-656.
Allie D, Hall P, Shammas NW, Safian R, Laird JR, Young JJ et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results. Journal of Invasive Cardiology. 2004 Nov;16(11):651-656.
Allie, David ; Hall, Patrick ; Shammas, Nicolas W. ; Safian, Robert ; Laird, John R. ; Young, John J. ; Virmani, Ajay. / The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE) : In-hospital and 30-day results. In: Journal of Invasive Cardiology. 2004 ; Vol. 16, No. 11. pp. 651-656.
@article{11d9c738f96949849e113d069956cdcf,
title = "The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): In-hospital and 30-day results",
abstract = "Background - High-risk patient characteristics and complexity of percutaneous peripheral intervention (PPI) procedures suggest a need for predictable and reliable anticoagulation. We undertook this study to assess the safety and efficacy of bivalirudin as the procedural anticoagulant in patients undergoing PPI of the renal, iliac, or femoral artery. Methods - This was a prospective, open-label, single arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant (0.75 mg/kg bolus/1.75 mg/kg/hr infusion). The primary endpoint was procedural success defined as residual stenosis ≤ 20{\%}. Secondary endpoints included ischemic events (death, myocardial infarction, unplanned revascularization, and amputation), and bleeding complications, as well as ACT values and times to sheath removal, ambulation, and discharge. Results - 505 patients were enrolled at 26 sites. Procedural success was achieved in 95.0{\%} of patients. Ischemic events were low (1.4{\%}) and similar between vessel types. Protocol-defined major hemorrhage and TIMI major hemorrhage rates were 2.2{\%} and 0.4{\%}, respectively. Mean ACTs were similar among treatment groups (renal 353.8 seconds(s); iliac 335.9s, femoral, 343.5s). Conclusion - Bivalirudin provided consistent anticoagulation and similar outcomes in all vessel types treated at the dose tested. Ischemic and bleeding event rates were low, demonstrating the safe use of bivalirudin as a procedural anticoagulant in PPI.",
keywords = "Anticoagulation, Femoral artery, Iliac artery, Percutaneous peripheral intervention, Renal intervention, Unfractionated heparin",
author = "David Allie and Patrick Hall and Shammas, {Nicolas W.} and Robert Safian and Laird, {John R.} and Young, {John J.} and Ajay Virmani",
year = "2004",
month = "11",
language = "English (US)",
volume = "16",
pages = "651--656",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "11",

}

TY - JOUR

T1 - The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE)

T2 - In-hospital and 30-day results

AU - Allie, David

AU - Hall, Patrick

AU - Shammas, Nicolas W.

AU - Safian, Robert

AU - Laird, John R.

AU - Young, John J.

AU - Virmani, Ajay

PY - 2004/11

Y1 - 2004/11

N2 - Background - High-risk patient characteristics and complexity of percutaneous peripheral intervention (PPI) procedures suggest a need for predictable and reliable anticoagulation. We undertook this study to assess the safety and efficacy of bivalirudin as the procedural anticoagulant in patients undergoing PPI of the renal, iliac, or femoral artery. Methods - This was a prospective, open-label, single arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant (0.75 mg/kg bolus/1.75 mg/kg/hr infusion). The primary endpoint was procedural success defined as residual stenosis ≤ 20%. Secondary endpoints included ischemic events (death, myocardial infarction, unplanned revascularization, and amputation), and bleeding complications, as well as ACT values and times to sheath removal, ambulation, and discharge. Results - 505 patients were enrolled at 26 sites. Procedural success was achieved in 95.0% of patients. Ischemic events were low (1.4%) and similar between vessel types. Protocol-defined major hemorrhage and TIMI major hemorrhage rates were 2.2% and 0.4%, respectively. Mean ACTs were similar among treatment groups (renal 353.8 seconds(s); iliac 335.9s, femoral, 343.5s). Conclusion - Bivalirudin provided consistent anticoagulation and similar outcomes in all vessel types treated at the dose tested. Ischemic and bleeding event rates were low, demonstrating the safe use of bivalirudin as a procedural anticoagulant in PPI.

AB - Background - High-risk patient characteristics and complexity of percutaneous peripheral intervention (PPI) procedures suggest a need for predictable and reliable anticoagulation. We undertook this study to assess the safety and efficacy of bivalirudin as the procedural anticoagulant in patients undergoing PPI of the renal, iliac, or femoral artery. Methods - This was a prospective, open-label, single arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant (0.75 mg/kg bolus/1.75 mg/kg/hr infusion). The primary endpoint was procedural success defined as residual stenosis ≤ 20%. Secondary endpoints included ischemic events (death, myocardial infarction, unplanned revascularization, and amputation), and bleeding complications, as well as ACT values and times to sheath removal, ambulation, and discharge. Results - 505 patients were enrolled at 26 sites. Procedural success was achieved in 95.0% of patients. Ischemic events were low (1.4%) and similar between vessel types. Protocol-defined major hemorrhage and TIMI major hemorrhage rates were 2.2% and 0.4%, respectively. Mean ACTs were similar among treatment groups (renal 353.8 seconds(s); iliac 335.9s, femoral, 343.5s). Conclusion - Bivalirudin provided consistent anticoagulation and similar outcomes in all vessel types treated at the dose tested. Ischemic and bleeding event rates were low, demonstrating the safe use of bivalirudin as a procedural anticoagulant in PPI.

KW - Anticoagulation

KW - Femoral artery

KW - Iliac artery

KW - Percutaneous peripheral intervention

KW - Renal intervention

KW - Unfractionated heparin

UR - http://www.scopus.com/inward/record.url?scp=8844241452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844241452&partnerID=8YFLogxK

M3 - Article

C2 - 15550739

AN - SCOPUS:8844241452

VL - 16

SP - 651

EP - 656

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 11

ER -